These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 36113878)

  • 21. [Neuroscientific and psychological explanations for the therapeutic effects of psychedelics].
    van Elk M
    Tijdschr Psychiatr; 2020; 62(8):677-683. PubMed ID: 32816296
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Naturalistic use of psychedelics does not modulate processing of self-related stimuli (but it might modulate attentional mechanisms): An event-related potentials study.
    Orłowski P; Hobot J; Ruban A; Szczypiński J; Bola M
    Psychophysiology; 2024 Aug; 61(8):e14583. PubMed ID: 38584307
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modalities of the psychedelic experience: Microclimates of set and setting in hallucinogen research and culture.
    Hartogsohn I
    Transcult Psychiatry; 2022 Oct; 59(5):579-591. PubMed ID: 35818775
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of Setting on Psychedelic Experiences, Therapies, and Outcomes: A Rapid Scoping Review of the Literature.
    Golden TL; Magsamen S; Sandu CC; Lin S; Roebuck GM; Shi KM; Barrett FS
    Curr Top Behav Neurosci; 2022; 56():35-70. PubMed ID: 35138585
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The potential of psychedelics for the treatment of Alzheimer's disease and related dementias.
    Winkelman MJ; Szabo A; Frecska E
    Eur Neuropsychopharmacol; 2023 Nov; 76():3-16. PubMed ID: 37451163
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Classic psychedelics in the treatment of substance use disorder: Potential synergies with twelve-step programs.
    Yaden DB; Berghella AP; Regier PS; Garcia-Romeu A; Johnson MW; Hendricks PS
    Int J Drug Policy; 2021 Dec; 98():103380. PubMed ID: 34329952
    [TBL] [Abstract][Full Text] [Related]  

  • 27. REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics.
    Carhart-Harris RL; Friston KJ
    Pharmacol Rev; 2019 Jul; 71(3):316-344. PubMed ID: 31221820
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interactions between classic psychedelics and serotonergic antidepressants: Effects on the acute psychedelic subjective experience, well-being and depressive symptoms from a prospective survey study.
    Barbut Siva J; Barba T; Kettner H; Kuc J; Nutt DJ; Carhart-Harris R; Erritzoe D
    J Psychopharmacol; 2024 Feb; 38(2):145-155. PubMed ID: 38281075
    [TBL] [Abstract][Full Text] [Related]  

  • 29. IUPHAR-review: The integration of classic psychedelics into current substance use disorder treatment models.
    Yaden DB; Berghella AP; Hendricks PS; Yaden ME; Levine M; Rohde JS; Nayak S; Johnson MW; Garcia-Romeu A
    Pharmacol Res; 2024 Jan; 199():106998. PubMed ID: 38029805
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Psychedelics and Psychotherapy.
    Nayak S; Johnson MW
    Pharmacopsychiatry; 2021 Jul; 54(4):167-175. PubMed ID: 33285578
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Psychedelic-Assisted Therapy for Social Adaptability in Autistic Adults.
    Danforth A
    Curr Top Behav Neurosci; 2022; 56():71-92. PubMed ID: 34761363
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Psychedelic unselfing: self-transcendence and change of values in psychedelic experiences.
    Kähönen J
    Front Psychol; 2023; 14():1104627. PubMed ID: 37388660
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Psychedelics and music: neuroscience and therapeutic implications.
    Barrett FS; Preller KH; Kaelen M
    Int Rev Psychiatry; 2018 Aug; 30(4):350-362. PubMed ID: 30240282
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population.
    Hendricks PS; Thorne CB; Clark CB; Coombs DW; Johnson MW
    J Psychopharmacol; 2015 Mar; 29(3):280-8. PubMed ID: 25586402
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Deepening our understanding of psychedelics by expanding psychedelic data collection in the United States National Survey on Drug Use and Health.
    Barnett BS
    J Psychopharmacol; 2022 Oct; 36(10):1097-1099. PubMed ID: 36112818
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Psychedelics in the treatment of unipolar and bipolar depression.
    Bosch OG; Halm S; Seifritz E
    Int J Bipolar Disord; 2022 Jul; 10(1):18. PubMed ID: 35788817
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of serotonergic psychedelics on mitochondria: Transdiagnostic implications for mitochondria-related pathologies.
    Fissler P; Vandersmissen A; Filippi M; Mavioglu RN; Scholkmann F; Karabatsiakis A; Krähenmann R
    J Psychopharmacol; 2023 Jul; 37(7):679-686. PubMed ID: 37122193
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lifetime experience with (classic) psychedelics predicts pro-environmental behavior through an increase in nature relatedness.
    Forstmann M; Sagioglou C
    J Psychopharmacol; 2017 Aug; 31(8):975-988. PubMed ID: 28631526
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Case analysis of long-term negative psychological responses to psychedelics.
    Bremler R; Katati N; Shergill P; Erritzoe D; Carhart-Harris RL
    Sci Rep; 2023 Sep; 13(1):15998. PubMed ID: 37749109
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.